1. Síndrome de hiperémesis por cannabis: incidencia y tratamiento con capsaicina tópica
- Author
-
David Trujillo-Burillo, John R. Richards, Guillermo Burillo-Putze, Jose Carlos García-Hernandez, M Angeles López-Hernández, Iván Hernández-Ramos, and Isabel Ramos-Suárez
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Incidence (epidemiology) ,Retrospective cohort study ,General Medicine ,Emergency department ,biology.organism_classification ,medicine.disease ,chemistry.chemical_compound ,Cannabinoid hyperemesis syndrome ,chemistry ,Capsaicin ,Internal medicine ,Epidemiology ,Vomiting ,medicine ,Cannabis ,medicine.symptom ,business - Abstract
There are few studies in Spain on cannabinoid hyperemesis syndrome (CHS), as well as on the use of topical capsaicin as a treatment. Methods Retrospective study of patients over 14 years of age seen in a hospital emergency department during 2018 and 2019 with a diagnosis of CHS based on the following criteria: compatible clinical picture, cannabis use less than 48h and positive urine cannabis test. Epidemiological and clinical variables, attendance times and treatment (including use of topical capsaicin 0.075%) were collected. Results Fifty-nine attendances were studied, from 29 patients (4.4 cases/10,000 visits, 95% CI 2.8-4.7). Fifty per cent returned for CHS, differing only in more tobacco (P=.01) and cocaine (P=.031) use. Capsaicin was used in 74.6% of visits. The mean time to resolution of vomiting after application was 17.87min. Conclusions Although probably underdiagnosed, CHS has a low incidence in the emergency department in Spain, with high patient recurrence. The use of capsaicin ointment is efficient and safe.
- Published
- 2022
- Full Text
- View/download PDF